• Findom_DeLuise [she/her, they/them]@hexbear.net
    link
    fedilink
    English
    arrow-up
    27
    ·
    3 months ago

    I mean, yeah, no shit, if it’s used by someone who is either hyperglycemic/pre-diabetic or who has full-on type 2 diabetes. Semaglutide helps to clamp down on excessive blood glucose floating around in the body due to insulin resistance. Having chronic high blood glucose like that fucks with everything from your kidneys to your heart, and also causes various issues with circulation and dry skin, which can give the appearance of premature aging.

    Of course, leave it to big pharma capitalist fucksticks (and their cronies at the BBC) to try to pitch it as some kind of miracle drug for every other goddamned thing that plagues humanity while keeping the price artificially inflated for as long as regulators will let them.

  • Hexboare [they/them]@hexbear.net
    link
    fedilink
    English
    arrow-up
    9
    ·
    3 months ago

    Here is the actual article

    The SELECT (Semaglutide Effects on Cardiovascular Outcomes in Patients With Overweight or Obesity) trial randomized 17,604 participants ≥45 years of age with a body mass index ≥27 kg/m2 with established CV disease but without diabetes to once-weekly subcutaneous semaglutide 2.4 mg or placebo; the mean trial duration was 3.3 years. Adjudicated causes of all deaths, COVID-19 cases, and associated deaths were captured prospectively.

    Of 833 deaths, 485 (58%) were CV deaths, and 348 (42%) were non-CV deaths. Participants assigned to semaglutide vs placebo had lower rates of all-cause death (HR: 0.81; 95% CI: 0.71-0.93), CV death (HR: 0.85; 95% CI: 0.71-1.01), and non-CV death (HR: 0.77; 95% CI: 0.62-0.95). The most common causes of CV death with semaglutide vs placebo were sudden cardiac death (98 vs 109; HR: 0.89; 95% CI: 0.68-1.17) and undetermined death (77 vs 90; HR: 0.85; 95% CI: 0.63-1.15). Infection was the most common cause of non-CV death and occurred at a lower rate in the semaglutide vs the placebo group (62 vs 87; HR: 0.71; 95% CI: 0.51-0.98). Semaglutide did not reduce incident COVID-19; however, among participants who developed COVID-19, fewer participants treated with semaglutide had COVID-19–related serious adverse events (232 vs 277; P = 0.04) or died of COVID-19 (43 vs 65; HR: 0.66; 95% CI: 0.44-0.96). High rates of infectious deaths occurred during the COVID-19 pandemic, with less infectious death in the semaglutide arm, and resulted in fewer participants in the placebo group being at risk for CV death.

    https://www.sciencedirect.com/science/article/pii/S0735109724081567

    • ClimateChangeAnxiety [he/him, they/them]@hexbear.net
      link
      fedilink
      English
      arrow-up
      14
      ·
      edit-2
      3 months ago

      High rates of infectious deaths occurred during the COVID-19 pandemic, with less infectious death in the semaglutide arm, and resulted in fewer participants in the placebo group being at risk for CV death.

      “So many people died from covid that we had to account for the fact that people who already died from covid couldn’t die from cardiovascular disease”

      Fucking bleak